

# Gene co-expression network and function modules in three types of glioma

GANG LI, WEIRAN PAN, XIAOXIAO YANG and JINMING MIAO

Department of Neurosurgery, Shengjing Hospital of China Medical University,  
Shenyang, Liaoning 110004, P.R. China

Received October 17, 2013; Accepted April 25, 2014

DOI: 10.3892/mmr.2014.3014

**Abstract.** The aim of the present study was to identify the disease-associated genes and their functions involved in the development of three types of glioma (astrocytoma, glioblastoma and oligodendroglioma) with DNA microarray technology, and to analyze their differences and correlations. First, the gene expression profile GSE4290 was downloaded from the Gene Expression Omnibus database, then the probe-level data were pre-processed and the differentially expressed genes (DEGs) were identified with limma package in R language. Gene functions of the selected DEGs were further analyzed with the Database for Annotation, Visualization and Integrated Discovery. After the co-expression network of DEGs was constructed by Cytoscape, the functional modules were mined and enrichment analysis was performed, and then the similarities and differences between any two types of glioma were compared. A total of 1151 genes between normal and astrocytoma tissues, 684 genes between normal and malignant glioma tissues, and 551 genes between normal and oligodendroglioma tissues were filtered as DEGs, respectively. By constructing co-expression networks of DEGs, a total of 77232, 455 and 987 interactions were involved in the differentially co-expressed networks of astrocytoma, oligodendroglioma and glioblastoma, respectively. The functions of DEGs were consistent with the modules in astrocytoma, glioblastoma and oligodendroglioma, which were mainly enriched in neuron signal transmission, immune responses and synthesis of organic acids, respectively. Model functions of astrocytoma and glioblastoma were similar (mainly related with immune response), while the model functions of oligodendroglioma differed markedly from that of the other two types. The identification of the associations among these three

types of glioma has potential clinical utility for improving the diagnosis of different types of glioma in the future. In addition, these results have marked significance in studying the underlying mechanisms, distinguishing between normal and cancer tissues, and examining novel therapeutic strategies for patients with glioma.

## Introduction

Glioma derived from glial cells is the most common type of primary intracerebral neoplasm, accounting for >40% of all primary brain tumors in humans (1), and typically has a poor prognosis (2). The classification of glioma varies depending on different standards. In the present study, the three most prevalent types of glioma that exhibit a high degree of malignancy were selected for in-depth analysis, astrocytoma, oligodendroglioma and glioblastoma. Astrocytoma has the highest morbidity; oligodendroglioma, which originates from the interstitial cells is more common than the neuronal tumor that originates from the parenchyma cells; while the medical history of glioblastoma is notably short (3).

Glioma has been the subject of an increasing number of studies over the past two decades, that has resulted in considerable advances in the understanding of basic biology and pathogenesis (3,4,5). This accumulative evidence is contributing to development of novel pharmacological strategies to target the key molecular pathways involved in gliomas and reduce the resulting mortality and morbidity by 2020 (6). Despite aggressive treatment with surgery, radiation and chemotherapy, the average survival time for glioma patients remains only 14 months (7). Therefore, more effective therapies are urgently required. Furthermore, due to the progressive nature of cancer, which involves multiple mutations, individual gene analysis may only provide limited insights into the cellular mechanisms underlying carcinogenesis (8). Therefore, further investigation of the pathogenetic basis of glioma is imperative.

In recent years, with the continuous development of biotechnology and the innovation of novel high throughput technology, studies have begun to investigate the occurrence and development of diseases at the genome level, and gene chip technology is commonly used to detect genome-wide gene expression at the transcriptome level. Numerous studies have screened biomarkers associated with diseases by analyzing gene expression profiling (9,10), and have analyzed the

---

*Correspondence to:* Dr Weiran Pan, Department of Neurosurgery, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping, Shenyang, Liaoning 110004, P.R. China  
E-mail: weiranpan@hotmail.com

**Key words:** glioma, gene expression profiling, differentially expressed gene, co-expression network, pathway enrichment analysis, function module mining

pathogenesis of various complex diseases (11) by associating the gene expression level with biological networks, including protein interaction networks (12), regulation and metabolic networks (13) and signal networks (14). The present study aimed to identify the disease-associated genes and gene functions in three types of glioma (astrocytoma, glioblastoma and oligodendroglioma) based on DNA microarray gene expression profiling and to analyze their differences and correlations, which may provide novel avenues for more advanced investigation into the mechanisms underlying glioma. Improving the understanding of the molecular mechanisms of glioma may provide evidence that aids in the development of early diagnosis and treatment strategies for patients.

## Materials and methods

**Microarray data.** Gene Expression Omnibus (GEO) (15) (<http://www.ncbi.nlm.nih.gov/geo/>) is currently the largest and most comprehensive public gene expression database. The gene expression data stored in GEO is mainly submitted from laboratories worldwide, including Affymetrix microarray data, expressed sequence tag sequence data, serial analysis of gene expression sequence data and second generation sequence data. Each set of the submitted expression profile data include information of platforms, sequences and samples. The gene expression profile GSE4290 (16) was downloaded from the GEO database, including 157 glioma tissue samples: 26 Astrocytoma, 81 glioblastoma, 50 oligodendroglioma and 23 normal tissue samples.

**Data preprocessing.** According to the corresponding correlation between the probe and gene from the GPL570 platform [HG-U133\_Plus\_2](Affymetrix Human Genome U 133 plus 2.0 Array; Affymetrix, Santa Clara, CA, USA) the probe numbers of the expression profile were converted into the corresponding gene symbols. One gene corresponds with multiple probes, thus each gene has more than one expression value. Therefore, the average value was calculated and selected as the only representative value. A total of 20308 genes were involved following processing. Background correction and quartile data normalization were performed by the robust multiarray average in R affy package (Affymetrix).

**Differentially expressed genes (DEGs) analysis.** The limma package (Affymetrix)(17) was used to identify the DEGs between the normal and three glioma tissues, respectively. The cut-off criterion was  $P < 0.01$ .

**Gene ontology (GO) enrichment analysis.** For preliminary investigation into the functional differences of DEGs in the three types of glioma, Database for Annotation, Visualization and Integrated Discovery (DAVID) online software (DAVID Bioinformatics Resources 6.7 <http://david.abcc.ncifcrf.gov/home.jsp>) was used to perform GO (18) enrichment analysis. DAVID (19) utilizes Fisher's exact test to enrich functions of certain genes. The cut-off criterion was the false discovery false corrected  $P < 0.01$ .

**Co-expression network construction of DEGs.** Multiple high-throughput expression data provide an opportunity for

global research on gene functions. Genes involved in the same pathway or same functional compound, in different time and physiological conditions, tend to demonstrate a similar expression pattern (20). Therefore, the construction of a gene co-expression network facilitates the identification of gene collections with similar functions (21). Gene co-expression networks were constructed in the following procedure. Firstly, the expression values of normal samples were removed from the expression profile data. Secondly, Pearson's correlation coefficient between two DEGs was calculated according to the formula below, and the pairs whose correlation was  $> 0.7$  were selected as the co-expressed gene pairs:

$$r = \frac{1}{n-1} \sum_{i=1}^n \left( \frac{X_i - \bar{X}}{\delta_X} \right) \left( \frac{Y_i - \bar{Y}}{\delta_Y} \right)$$

Where  $r$  is the Pearson's correlation coefficient;  $n$  is the sample size;  $\bar{X}$  is the average of sample  $X$ ;  $\bar{Y}$  is the average of sample  $Y$ ;  $\delta_X$  is the standard deviation of sample  $X$ ; and  $\delta_Y$  is the standard deviation of sample  $Y$ . Finally, clusterviz package in Cytoscape (22) was used to construct the co-expression network (1).

**Function module mining and analysis.** MCODE (23) was used to mine the function modules in the co-expression networks. The MCODE algorithm includes three steps: (i) The weight calculation of network vertex; (ii) the compound prediction; and (iii) the subsequent node filter or addition of the compound based on certain connection indicators. The network clustering coefficient  $C_i$  was selected as the node weight [ $C_i = 2 \cdot n / (K_i \cdot (K_i - 1))$ ], where  $K_i$  represents the node number directly connected with the node  $i$ , and  $n$  represents the connected edge number of these nodes. The node with the largest weight was taken as seed to search the node  $j$  whose weight ratio ( $W_j / W_{\text{seed}}$ ) was greater than a certain threshold. The value of the  $j$  node was considered, to repeat the search. A module was constituted until the threshold value was met. The searched nodes were removed from the network, so the searching number of each node was not  $> 1$ . Next, the modules, which included  $> 10$  genes in the networks, were selected to perform the Gene Ontology enrichment analysis by DAVID.

## Results

**DEG analysis.** A total of 1151 genes between normal and astrocytoma tissues, 684 genes between normal and glioblastoma tissues, and 551 genes between normal and oligodendroglioma tissues were filtered as DEGs, respectively.

**Function enrichment of DEGs.** Following the GO enrichment analysis, it was identified that the functions of DEGs in the three types of glioma were significantly different. The DEGs in astrocytoma were mainly involved in neuron signal transmission processes, including the synapse, synapse part and synaptic transmission (Table I). The DEGs of the glioblastoma were mainly involved in the immune response and antigen processing (Table II), and for oligodendroglioma, the DEGs were mainly involved in signal transmission processes, including GTPase activity and GTP binding (Table III).

Table I. Enriched functions of DEGs in astrocytoma (top 10).

Category	Term	FDR
GOTERM_CC_FAT	GO:0045202~synapse	2.04E-32
GOTERM_CC_FAT	GO:0044456~synapse part	3.31E-30
GOTERM_BP_FAT	GO:0007268~synaptic transmission	3.95E-24
GOTERM_BP_FAT	GO:0019226~transmission of nerve impulse	1.35E-23
GOTERM_CC_FAT	GO:0008021~synaptic vesicle	5.25E-19
GOTERM_CC_FAT	GO:0043005~neuron projection	5.03E-18
GOTERM_BP_FAT	GO:0007267~cell-cell signaling	5.27E-17
GOTERM_CC_FAT	GO:0044459~plasma membrane part	3.11E-15
GOTERM_CC_FAT	GO:0005886~plasma membrane	6.22E-13

FDR, false discovery rate; DEGs, differentially expressed genes; GO, Gene ontology.

Table II. Enriched functions of DEGs in glioblastoma (top 10).

Category	Term	FDR
GOTERM_BP_FAT	GO:0006955~immune response	5.61E-09
GOTERM_BP_FAT	GO:0048002~antigen processing and presentation of peptide antigen	1.64E-06
GOTERM_BP_FAT	GO:0019882~antigen processing and presentation	4.60E-06
KEGG_PATHWAY	hsa05416:Viral myocarditis	3.44E-04
GOTERM_CC_FAT	GO:0042611~MHC protein complex	4.49E-04
KEGG_PATHWAY	hsa04612:Antigen processing and presentation	2.53E-03
GOTERM_CC_FAT	GO:0000323~lytic vacuole	3.52E-03
GOTERM_CC_FAT	GO:0005764~lysosome	3.52E-03
GOTERM_CC_FAT	GO:0042612~MHC class I protein complex	3.67E-03
KEGG_PATHWAY	hsa05330:Allograft rejection	6.27E-03

FDR, false discovery rate; DEGs, differentially expressed genes; GO, Gene ontology.

Table III. Enriched functions of DEGs in oligodendroglioma (top 10).

Category	Term	FDR
GOTERM_MF_FAT	GO:0003924~GTPase activity	1.282379
GOTERM_MF_FAT	GO:0005525~GTP binding	3.882750
GOTERM_CC_FAT	GO:0043233~organelle lumen	3.790407
GOTERM_CC_FAT	GO:0031974~membrane-enclosed lumen	3.855442
GOTERM_BP_FAT	GO:0032989~cellular component morphogenesis	5.467166
GOTERM_MF_FAT	GO:0032561~guanyl ribonucleotide binding	5.117207
GOTERM_MF_FAT	GO:0019001~guanyl nucleotide binding	5.117207
GOTERM_BP_FAT	GO:0000902~cell morphogenesis	8.180084
GOTERM_MF_FAT	GO:0008134~transcription factor binding	7.159959
GOTERM_CC_FAT	GO:0070013~intracellular organelle lumen	8.253551

FDR, false discovery rate; DEGs, differentially expressed genes; GO, Gene ontology.

*Co-expression networks of DEGs.* Co-expression networks of the three types of glioma were constructed, and the genes with a Pearson's correlation coefficient >0.7 were selected as the co-expressed gene pairs. A total of 77232, 455 and 987

interactions were involved in the differentially co-expressed networks of astrocytoma (Fig. 1), oligodendroglioma (Fig. 2) and glioblastoma (Fig. 3), respectively. From the three co-expression networks it was observed that they all had

Table IV. Enriched functions of astrocytoma modules.

Module	Function ID	Description	P-value
Module1	GO:0022836	Gated channel activity (MF)	3.549E-13
	GO:0022839	Iron gated channel activity (MF)	3.549E-13
	GO:0005216	Iron channel activity (MF)	5.003E-12
	GO:0022838	Substrate-specific channel activity (MF)	9.450E-12
	GO:0005215	Transporter activity (MF)	1.099E-11
	GO:0007268	Synaptic transmission (BP)	3.940E-46
	GO:0035637	Multicellular organismal signaling (BP)	1.496E-44
	GO:0019226	Transmission of nerve impulse (BP)	3.705E-43
	GO:0007267	Cell-cell signaling (BP)	3.354E-39
	GO:0050877	Neurological system process (BP)	5.294E-35
	GO:0045202	Synapse (CC)	1.230E-41
	GO:0097458	Neuron part (CC)	1.414E-37
	GO:0044456	Synapse part (CC)	6.823E-35
	GO:0043005	Neuron projection (CC)	1.610E-33
	GO:0008021	Synaptic vesicle (CC)	4.156E-22
Module2	GO:0070891	Lipoteichoic acid binding (MF)	3.231E-3
	GO:0019864	IgG binding (MF)	4.791E-2
	GO:0006955	Immune response (BP)	1.753E-13
	GO:0006952	Defense response (BP)	5.365E-12
	GO:0002682	Regulation of immune system process (BP)	1.062E-10
	GO:0050776	Regulation of immune response (BP)	1.538E-10
	GO:0045087	Innate immune response (BP)	2.973E-8
	GO:0044420	Extracellular matrix part (CC)	2.914E-7
	GO:0005764	Lysosome (CC)	4.999E-6
	GO:0000323	Lytic vacuole (CC)	4.999E-6
	GO:0042611	MHC protein complex (CC)	9.777E-6
	GO:0005773	Vacuole (CC)	2.442E-5

MF, molecular function; BP, biological process; CC, cellular component; GO, Gene ontology.

significantly different modularity, so their functions exhibited different emphases.

**Function module mining and analysis.** The MCODE method was used to mine the network modules. A total of 32, 7 and 10 modules were excavated from the differential co-expression networks of astrocytoma, glioblastoma and oligodendroglioma, respectively. The five modules with the maximum number of genes selected from the networks of the three types of glioma are demonstrated in Fig. 4. The modules that included >10 genes in the networks of the three types of glioma were selected for GO enrichment analysis.

The functions of the five modules of astrocytoma showed the diverse regulation of astrocytoma: Module1 was mainly involved in the function of neural signal transmission, including synaptic transmission, multicellular organismal signaling and transmission of nerve impulse. The functions of Module2 were mainly associated with the immune response, defense response and regulation of immune system processes. The functions of Module3 were mainly correlated with the myelin sheath. The functions of Module4 were mainly associated with the cell cycle and Module5 was mainly involved in signal transmission functions. Among

them, the functions of Module1 and Module2 were summarized in Table IV. PAK3 p21-activated kinase 3 (PAK3) and docking protein 6 (DOK-6) were two genes in these modules.

Only two modules of the glioblastoma network contained >10 genes, and their enriched functions are demonstrated in Table V. Module1 was mainly enriched in functions related to immune response, regulation of immune responses and defense responses. Module2 was mainly enriched in biological processes, including cytoskeletal anchoring at plasma membrane, protein phosphorylation and regulation of sodium ion transport. CD86 and WNK lysine deficient protein kinase 2 (WNK2) were two genes in these modules.

Only one module was excavated with >10 genes in the differentially co-expressed network of oligodendroglioma, and it was identified that its functions were mainly enriched in the synthesis of organic acids. Cyclin-dependent kinase 5 (Cdk5) and DOK-6 were two genes in the module.

## Discussion

Glioma is a multi-stage process, involving a variety of changes in gene expression and physiological structure, such as the



Table V. Enriched functions of glioblastoma modules.

Module	Function ID	Description	P-value
Module1	GO:0019864	IgG binding (MF)	2.942E-2
	GO:0032395	MHC class II receptor activity (MF)	4.304E-2
	GO:0006955	Immune response (BP)	8.795E-10
	GO:0050776	Regulation of immune response (BP)	7.431E-8
	GO:0006952	Defense response (BP)	2.940E-7
	GO:0045087	Innate immune response (BP)	1.039E-6
	GO:0002253	Activation of immune response (BP)	1.754E-5
	GO:0005887	Integral to plasma membrane (CC)	8.919E-5
	GO:0031226	Intrinsic to plasma membrane (CC)	1.333E-4
	GO:0005764	Lysosome (CC)	9.638E-3
	GO:0000323	Lytic vacuole (CC)	9.638E-3
	GO:0044437	Vacuolar part (CC)	2.198E-2
Module2	GO:0070853	Myosin VI binding (MF)	2.404 E-2
	GO:0005200	Structural constituent of cytoskeleton (MF)	3.074E-2
	GO:0007016	Cytoskeletal anchoring at plasma membrane (BP)	2.365E-3
	GO:0046777	Protein autophosphorylation (BP)	1.682E-2
	GO:0002028	Regulation of sodium ion transport (BP)	4.280E-2

MF, molecular function; BP, biological process; CC, cellular component; GO, Gene ontology.




Figure 1. Differentially co-expressed network of differentially expressed genes in astrocytoma.






Figure 3. Differentially co-expressed network of differentially expressed genes oligodendrogloma.




Figure 4. Five modules with the maximum number of genes selected respectively from the networks of the three types of glioma.

previously demonstrated to be implicated in glioma invasion (28,29), and PAK is a potential therapeutic target in schwannomas (30). DOK-6 expression was relatively high

in several human neuroblastoma cell lines and detected in the developing neocortex, diencephalon, spinal cord and cranial parasympathetic nerve (31), which suggests that



it has functional roles in neuronal cells. Understanding signal transmission within neural cells is a crucial issue in neuroscience. Nervous system signaling disorders are known to cause numerous diseases, including Parkinson's disease, Alzheimer's disease and cancer (32). DEGs identified in astrocytoma tissues were mainly associated with synaptic signaling, thus novel drugs may be identified that interfere with these pathways.

CD86, a co-stimulatory molecule, is downregulated in glioblastoma to evade immune recognition (33). WNK2 acts as a recurrent target for epigenetic silencing in glia-derived brain tumors and is associated with tumor cell invasion and proliferation (34). One study indicated that the loss of WNK2 expression may contribute to the highly invasive phenotype of glioblastomas and it is important for tumor cell survival and cell cycle progression (35). Protein phosphorylation is involved in the majority of cellular processes and thousands of distinct phosphorylation events may be detected in a single cell type (36). Enrichment analysis of the genes identified through the kinase-substrate network approach suggested that genes encoding phosphorylated signaling hubs are often disease-associated genes, and genes encoding conserved phosphoproteins are associated with cancer (37). Phorbol esters are tumor promoters and mitogens, whose effects may be mediated by changes in ion transport across membranes. They activate the physiological amiloride- and cAMP-sensitive channels gating apical Na<sup>+</sup> entry from the mucosal medium into the epithelial cells, which is associated with tumor occurrence (38,39). DEGs in the glioblastoma tissues were mainly associated with protein phosphorylation and sodium ion transportation, thus further studies are required to determine whether the genes identified in this study may be targeted clinically in the treatment of glioma.

It has been demonstrated that Cdk5 (40) and DOK-6 (31) were upregulated in oligodendrogloma tissues and have roles in the occurrence of oligodendrogloma. Recent studies have demonstrated that organic acids are cytotoxic against numerous human tumor types, including neuroectodermal and malignant brain tumors (41,42). With regard to its anticancer properties, betulinic acid (a type of organic acid) was previously reported to exhibit selective cytotoxicity against several melanoma-derived cell lines (41). Due to its selective cytotoxicity against tumor cells and favorable therapeutic index, betulinic acid is a highly promising novel chemotherapeutic agent for the treatment of cancer (43). DEGs in oligodendrogloma tissue were mainly those associated with the synthesis of organic acids, and this analysis may aid in the development of novel treatment strategies for the disease.

Reasonable use of microarray gene expression profiling not only renders the analysis of large quantities of biological information quick and simple, but also facilitates the accurate identification of the key molecular mechanisms associated with glioma biological behavior. In the present study, it was demonstrated that distinct treatments should be administered for the three types of glioma, due to their different functions analyzed from the mined network modules. Furthermore, the results of the present study implied that PAK3 and DOK-6, CD86 and WNK2, and Cdk5 may possibly be the target genes relevant to astrocytoma, glioblastoma and oligodendrogloma respectively. This may be useful in investigating the complex

interacting mechanisms underlying the disease, and provides a novel strategy, which may aid with the development of novel therapies for the different types of glioma. However, further studies are required to confirm these results and determine their clinical utility.

## Acknowledgements

The authors would like to thank Fenghe (Shanghai) Information Technology Co., Ltd. for their ideas and help, which provided a valuable added dimension to the study.

## References

1. Chen H, Chen Y, Zhao Y, *et al*: Association of sequence variants on chromosomes 20, 11, and 5 (20q13.33, 11q23.3, and 5p15.33) with glioma susceptibility in a chinese population. *Am J Epidemiol* 173: 915-922, 2011.
2. Parney IF: Basic concepts in glioma immunology. *Adv Exp Med Biol* 746: 42-52, 2012.
3. Huse JT and Holland EC: Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. *Nat Rev Cancer* 10: 319-331, 2010.
4. Rodenhiser D. and Mann M: Epigenetics and human disease: translating basic biology into clinical applications. *CMAJ* 174: 341-348, 2006.
5. Cobbs CS: Evolving evidence implicates cytomegalovirus as a promoter of malignant glioma pathogenesis. *Herpesviridae* 2: 10, 2011.
6. Van Meir EG, Hadjipanayis CG, Norden AD, *et al*: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. *CA Cancer J Clin* 60: 166-193, 2010.
7. Stupp R, Mason WP, van den Bent MJ, *et al*: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 352: 987-996, 2005.
8. Nibbe RK, Koyutürk M, and Chance MR: An integrative -omics approach to identify functional sub-networks in human colorectal cancer. *PLoS Comput Biol* 6: e1000639, 2010.
9. Zhu XL, Ai ZH, Wang J, Xu YL and Teng YC: Weighted gene co-expression network analysis in identification of endometrial cancer prognosis markers. *Asian Pac J Cancer Prev* 13: 4607-4611, 2012.
10. García-Claver A, Lorente M, Mur P, *et al*: Gene expression changes associated with erlotinib response in glioma cell lines. *Eur J Cancer* 49: 1641-1653, 2013.
11. Chen J, Ma M, Shen N, Xi JJ and Tian W: Integration of cancer gene co-expression network and metabolic network to uncover potential cancer drug targets. *J Proteome Res* 12: 2354-2364, 2013.
12. Laenen G, Thorrez L, Börnigen D and Moreau Y: Finding the targets of a drug by integration of gene expression data with a protein interaction network. *Mol Biosyst* 9: 1676-1685, 2013.
13. Morine MJ, Toomey S, McGillicuddy FC, *et al*: Network analysis of adipose tissue gene expression highlights altered metabolic and regulatory transcriptomic activity in high-fat-diet-fed IL-1RI knockout mice. *J Nutr Biochem* 24: 788-795, 2012.
14. Ho S, Chao Y, Tong W and Yu S: Sugar coordinately and differentially regulates growth-and stress-related gene expression via a complex signal transduction network and multiple control mechanisms. *Plant Physiol* 125: 877-890, 2001.
15. Barrett T, Suzek TO, Troup DB, *et al*: NCBI GEO: mining millions of expression profiles - database and tools. *Nucleic Acids Res* 33: D562-D566, 2005.
16. Sun L, Hui AM, Su Q, *et al*: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. *Cancer Cell* 9: 287-300, 2006.
17. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol* 3: 3, 2004.
18. Harris MA, Clark J, Ireland A, *et al*: The Gene Ontology (GO) database and informatics resource. *Nucleic Acids Res* 32: D258-D261, 2004.
19. Dennis G Jr, Sherman BT, Hosack DA, *et al*: DAVID: database for annotation, visualization, and integrated discovery. *Genome Biol* 4: P3, 2003.



20. Hong S, Dong H, Jin L and Xiong M: Gene co-expression network and functional module analysis of ovarian cancer. *Int J Comput Biol Drug Des* 4: 147-164, 2011.
21. Pyon YS, Li X and Li J: Cancer progression analysis based on ordinal relationship of cancer stages and co-expression network modularity. *Int J Data Min Bioinform* 5: 233-251, 2011.
22. Praneenararat T, Takagi T and Iwasaki W: Integration of interactive, multi-scale network navigation approach with cytoscape for functional genomics in the big data era. *BMC Genomics* 13 (Suppl 7): S24, 2012.
23. Bader GD and Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. *BMC Bioinformatics* 4: 2, 2003.
24. Marumoto T and Saya H: Molecular biology of glioma. *Adv Exp Med Biol* 746: 2-11, 2012.
25. Dougan M, Li D, Neuberg D, *et al*: A dual role for the immune response in a mouse model of inflammation-associated lung cancer. *J Clin Invest* 121: 2436-2446, 2011.
26. Berzofsky JA, Terabe M and Wood LV: Strategies to use immune modulators in therapeutic vaccines against cancer. *Semin Oncol* 39: 348-357, 2012.
27. Tang Y, He W, Wei Y, *et al*: Screening key genes and pathways in glioma based on gene set enrichment analysis and meta-analysis. *J Mol Neurosci* 50: 324-332, 2013.
28. Tenan M, Aurrand-Lions M, Widmer V, *et al*: Cooperative expression of junctional adhesion molecule-C and -B supports growth and invasion of glioma. *Glia* 58: 524-537, 2010.
29. Kissil JL, Blakeley JO, Ferner RE, *et al*: What's new in neurofibromatosis? Proceedings from the 2009 NF conference: new frontiers. *Am J Med Genet A* 152: 269-283, 2010.
30. Flaiz C, Chernoff J, Ammoun S, Peterson JR and Hanemann CO: PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. *Exp Neurol* 218: 137-144, 2009.
31. Kurotsuchi A, Murakumo Y, Jijiwa M, *et al*: Analysis of DOK-6 function in downstream signaling of RET in human neuroblastoma cells. *Cancer Sci* 101: 1147-1155, 2010.
32. Liao LD, Chang YJ, Lai HY, *et al*: A novel light-addressable multi-electrode array chip for neural signal recording based on vcsel diode arrays. *J Neurosci and Neuroeng* 1: 4-12, 2012.
33. Cheema TA, Wakimoto H, Fecci PE, *et al*: Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. *Proc Natl Acad Sci USA* 110: 12006-12011, 2013.
34. Moniz S, Martinho O, Pinto F, *et al*: Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. *Hum Mol Genet* 22: 84-95, 2013.
35. Moniz S, Martinho O, Reis RM and Jordan P: Protein kinase WNK2 regulates cell migration in malignant gliomas. <http://hdl.handle.net/10400.18/243>. Accessed 2011.
36. Hunter T: Regulation of cell signaling by protein phosphorylation, ubiquitylation and SUMOylation. Hong Kong University of Science and Technology, 2012.
37. Tan CSH, Bodenmiller B, Pasculescu A, *et al*: Comparative analysis reveals conserved protein phosphorylation networks implicated in multiple diseases. *Sci Signal* 2: ra39, 2009.
38. Civan MM, Rubenstein D, Mauro T and O'Brien TG: Effects of tumor promoters on sodium ion transport across frog skin. *Am J Physiol Cell Physiol* 248: C457-C465, 1985.
39. Tamai I, Ohashi R, Nezu J-I, *et al*: Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. *J Biol Chem* 273: 20378-20382, 1998.
40. Kremer D, Aktas O, Hartung HP and Küry P: The complex world of oligodendroglial differentiation inhibitors. *Ann Neurol* 69: 602-618, 2011.
41. Fulda S: Betulinic acid for cancer treatment and prevention. *Int J Mol Sci* 9: 1096-1107, 2008.
42. Jaggi M, Ramadoss S, Rajendran P and Siddiqui MJA: Betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis. US Patent 6,403,816. Filed September 20, 1999; issued June 11, 2002.
43. Cichewicz RH and Kouzi SA: Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. *Med Res Rev* 24: 90-114, 2004.